PMID- 33247665
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20201201
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 68
IP  - 12[Special]
DP  - 2020 Dec
TI  - In the Spotlight: Role of Gla-100 in the Glycemic Management of Hospitalized 
      people with diabetes.
PG  - 55-59
AB  - Both hyperglycemia and hypoglycemia in hospitalized patients represent a major 
      concern as they are associated with adverse outcomes-including increased rates of 
      infection, longer hospital stay, and even death. Insulin therapy is the mainstay 
      in the management of inpatient hyperglycemia. The traditional approach of sliding 
      scale insulin (SSI) therapy for the temporary management of blood glucose levels 
      in hospitalized patients, has now given way to basal-bolus insulin (BBI) therapy. 
      This is owing to the BBI affording a better glycemic control in non-critical 
      hospital settings as observed in multiple clinical studies using insulin glargine 
      100 U/mL (Gla-100) as the basal component. Furthermore, a string of clinical 
      studies has also attested to Gla-100 being used effectively even in patients on 
      corticosteroids, enteral or parenteral nutrition, and in perioperative settings. 
      Hence, overall, the existing evidence would point to the growing role of BBI 
      regimens centering around basal insulin like Gla-100 as an effective option with 
      low safety concerns for insulin therapy in both hospitalized and out-patient 
      settings in the treatment of patients with type 2 diabetes mellitus (T2DM).
CI  - (c) Journal of the Association of Physicians of India 2011.
FAU - Chatterjee, Sudip
AU  - Chatterjee S
AD  - Senior Consultant Endocrinologist, Park Clinic, Kolkata. West Bengal.
FAU - Chawla, Rajeev
AU  - Chawla R
AD  - Senior Consultant, North Delhi Diabetes Centre, Rohini, New Delhi.
FAU - Prakash, Arul
AU  - Prakash A
AD  - Senior Consultant Endocrinologist, Indra Diabetes Clinic, Tirunelveli, Tamil 
      Nadu.
FAU - Santosh, R
AU  - Santosh R
AD  - Senior Consultant Endocrinologist, Magna CODE Hospital, Chennai, Tamil Nadu.
FAU - Swain, Jayshree
AU  - Swain J
AD  - Consultant Endocrinologist, Diabetes and Endo-care Clinic, Cuttack, Odisha.
FAU - Jaiswal, Abhishek Arun
AU  - Jaiswal AA
AD  - Consultant endocrinologist, Vishudh Diabetes Clinic, Lucknow, Uttar Pradesh.
FAU - Bhattacharjee, Bikash
AU  - Bhattacharjee B
AD  - Consultant Diabetologist, Sunvalley Diabetic Care and Research Center, Guwahati, 
      Assam.
FAU - Lalan, Bhavesh
AU  - Lalan B
AD  - Medical Affairs, Diabetes and Cardiovascular, Sanofi India Ltd., Mumbai, 
      Maharashtra.
FAU - Mohan, Viswanathan
AU  - Mohan V
AD  - Chairman and Chief Diabetologist, Dr. Mohan's Diabetes Specialities Centre, 
      Chennai, Tamil Nadu.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 2ZM8CX04RZ (Insulin Glargine)
SB  - IM
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Humans
MH  - *Hyperglycemia/drug therapy
MH  - *Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents
MH  - Insulin
MH  - Insulin Glargine
EDAT- 2020/11/29 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/11/28 10:08
PHST- 2020/11/28 10:08 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PST - ppublish
SO  - J Assoc Physicians India. 2020 Dec;68(12[Special]):55-59.